Skip to main content

Biomarin Pharmaceuticals(BMRN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low54.78
Day High55.89
Open:55.45
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Biomarin Pharmaceuticals

Select a category then submit the form to load news
Tipranks
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS)
Tipranks
BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials
Motley Fool
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Motley Fool
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
Motley Fool
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
StockStory
2 Mid-Cap Stocks with Exciting Potential and 1 We Question
PINS
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
Motley Fool
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
Tipranks
H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)
StockStory
2 Reasons to Like BMRN (and 1 Not So Much)
BMRN
Motley Fool
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Tipranks
Barclays Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
Tipranks
BioMarin Earnings Call Highlights Growth, Pipeline, Deals
Tipranks
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and BioMarin Pharmaceutical (BMRN)
Tipranks
Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Tipranks
Cantor Fitzgerald Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT)
StockStory
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates
BMRN
StockStory
BioMarin Pharmaceutical Earnings: What To Look For From BMRN
BMRN
Tipranks
BioMarin Pharmaceutical (BMRN) Receives a Buy from Bernstein
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Vanda (VNDA) and BioMarin Pharmaceutical (BMRN)
Tipranks
BioMarin Pharmaceutical (BMRN) Receives a Buy from Canaccord Genuity
Tipranks
BioMarin Raises $850 Million Notes for Amicus Acquisition
Tipranks
BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies
Motley Fool
Should You Buy BioMarin Pharmaceutical Before Feb. 18?
Tipranks
BioMarin Secures Major Debt Financing for Amicus Acquisition
Tipranks
BioMarin Announces Major Debt Financing for Amicus Acquisition
Tipranks
BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors

Profile

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.